SureAdhere Mobile Technology

What SureAdhere Mobile Technology does

SureAdhere Mobile Technology operates a Video Directly Observed Therapy (VDOT) platform that enables healthcare providers to remotely monitor patient medication adherence without requiring in-person visits. The platform consists of two integrated components: a Provider Web Application for patient management, dosing review, real-time adherence analytics, triage, secure messaging, and live video visits, and a Patient Mobile App for recording and uploading medication adherence videos, receiving configurable dose reminders, and communicating with providers. SureAdhere originated from research at UC San Diego in 2009, was commercialized between 2014-2016, and was acquired by Dimagi in March 2022 to support growth and expansion. It integrates with EHRs, IRT, EDC, and CDR systems, as well as remote monitoring devices including wearables, pill bottles, cough detectors, and blood pressure monitors, and holds HIPAA, GDPR, CFR Part 11, and SOC 2 certifications.

The platform serves three primary verticals: public health (CDC-validated video-based DOT for TB and infectious disease), behavioral health (virtual Medication-Assisted Treatment for opioid use disorder), and clinical trials (adherence monitoring and data-driven regimen decisions even in low-connectivity settings). SureAdhere reports 96% treatment completion in the 2016 New York City TB study, 98% patient engagement after one year in the Vermont Wheels & Waves MAT study, 27 peer-reviewed publications contributing to CDC and WHO TB treatment guidelines, 800,000+ medication adherence videos processed, and deployment across 18 countries and 350+ healthcare and clinical programs.

Revenue is generated through a subscription SaaS model sold via an enterprise field sales motion to healthcare providers, public health departments, and clinical research organizations, with pricing handled through quote-based demo requests rather than publicly disclosed tiers. Notable named customers include the San Francisco Department of Public Health and Williamson County Health Department. The platform is marketed through the Dimagi corporate website, blog, podcast, and industry conferences, with WHO endorsement (2017-2018) and CDC recommendation (2023) as key regulatory tailwinds. Leadership comprises Kelly M. Collins (CEO), Dan Luis (Co-founder), and Richard Garfein (Chief Science Officer).

Name

SureAdhere Mobile Technology

Legal name

SureAdhere Mobile Technology

Website

https://sureadhere.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

SureAdhere Mobile Technology operates a Video Directly Observed Therapy platform that enables healthcare providers, public health departments, and clinical research organizations to remotely monitor patient medication adherence via patient-recorded videos and a provider web application, serving TB, behavioral health, and clinical trial use cases across 18 countries.

Ownership category

akta.pro rank

Product category

Digital Health Adherence Software

NAICS

Ambulatory Health Care Services (621), Other Ambulatory Health Care Services (6219)

akta.pro primary industry

Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)

akta.pro secondary industries

Medication Adherence & Therapy Management Platforms (refills, reminders, MTM) (HLALAIAG), Patient App, Adherence & Engagement for RPM Programs (HLACAFAJ)

Keywords

• Video directly observed therapy
• Medication adherence software
• Tuberculosis treatment monitoring
• Clinical trial adherence
• Digital health platform

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Healthcare Provider Subscription: Subscription-based SaaS model providing the SureAdhere platform to healthcare providers, public health departments, and clinical research organizations for medication adherence monitoring

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

SureAdhere provides a Video Directly Observed Therapy (VDOT) mobile health platform sold to healthcare providers, public health departments, and clinical research organizations. The offering combines a Provider Web Application for patient management, dose tracking, and real-time adherence analytics with a Patient Mobile App that records and uploads medication adherence videos, sends dose reminders, and supports secure messaging and live video visits. The platform supports tuberculosis and infectious disease treatment, medication-assisted treatment for opioid use disorder, and clinical trial adherence, with interoperability for EHR, IRT, EDC, and CDR systems.

Product overview

SureAdhere is a unified patient engagement platform built around video Directly Observed Therapy (vDOT). The core platform consists of two main components: the Provider Web Application (for healthcare providers to manage patients, review videos, and access real-time analytics) and the Patient Mobile App (for patients to record medication adherence videos, receive reminders, and communicate with providers). The platform serves public health (TB treatment), behavioral health (medication-assisted treatment for opioid use disorder), and clinical trials. It is offered by Dimagi alongside related products CommCare (mobile application platform) and Connect (data management platform).

Differentiator

Problem solved

Functional benefit

Products and services

• SureAdhere Platform Unified patient engagement platform built around Video Directly Observed Therapy (VDOT) for healthcare providers, public health departments, and clinical research organizations managing complex medication regimens. Combines a Provider Web Application and Patient Mobile App to enable remote adherence verification, dosing review, triage, secure messaging, and live video visits. Sold to enterprise healthcare buyers under a subscription SaaS model.
• SureAdhere Provider Web Application Provider-facing web application for managing patients on complex medication regimens, including dosing review, patient triage, follow-up engagement, real-time adherence analytics, secure messaging, and live video visits. Sold to healthcare providers and clinical research organizations as part of the SureAdhere subscription offering.
• SureAdhere Patient Mobile App Patient-facing mobile application that records and uploads medication adherence videos for Directly Observed Therapy verification, delivers dose reminders, tracks treatment progress on a treatment calendar, and supports secure messaging and live video visits with providers. Distributed to patients through subscribing healthcare providers and works offline for low-connectivity environments.

Quantifiable outcome

• 96% treatment completion rate for Tuberculosis treatment outcomes (2016 New York City Study)
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability2 records

Feature8 records

Partnerships

One partnership is on record.

• DimagicoreOthers · 1 January 2022SureAdhere was acquired by Dimagi in March 2022 to support growth and expansion. Dimagi is the parent company that owns and operates the SureAdhere platform. The acquisition enables SureAdhere to leverage Dimagi's global services infrastructure and support capabilities.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• emocha Mobile Health / Inseparable: emocha (now part of Inseparable) provides asynchronous video directly observed therapy primarily for TB and MAT, the closest direct competitor to SureAdhere in the VDOT niche serving similar public health and behavioral health programs.
• AiCure: AiCure uses computer vision and AI on patient smartphone video to confirm medication ingestion for clinical trials and adherence programs, a comparable technology approach and target customer set (sponsors and providers) as SureAdhere.
• Medisafe: Medisafe is a medication adherence platform combining patient-facing reminders, education, and provider dashboards across multiple chronic conditions, offering an adjacent adherence-focused SaaS model for payers, providers, and pharma.
• Wellth: Wellth applies behavioral economics and daily check-ins via smartphone to drive medication adherence for health plans and providers, serving overlapping chronic care populations with remote adherence tooling.
• AdhereTech: AdhereTech builds smart pill bottles and connected packaging for adherence monitoring, offering a hardware-led alternative to SureAdhere's video-based approach for the same goal of remote confirmation of dosing.
• Propeller Health (ResMed): Propeller Health provides connected inhalers and digital adherence support for respiratory patients (asthma, COPD), a comparable connected-device plus software adherence model serving chronic disease populations.

Emerging players

• etectRx: etectRx develops ingestible event marker (digital pill) sensors for adherence confirmation, an emerging adherence technology that competes for the same clinical trial and adherence-monitoring dollars as SureAdhere.

Broad incumbents

• Caregility: Caregility is a broader inpatient virtual care and telehealth platform used by hospitals and health systems, an incumbent that bundles video engagement and could overlap with SureAdhere's provider video workflows in adjacent deployments.
• Biofourmis: Biofourmis offers remote patient monitoring and digital therapeutics for chronic conditions including heart failure and oncology, an incumbent with adjacent technology and overlapping enterprise customers in connected care.

Others

• Dimagi (CommCare): Dimagi is SureAdhere's parent company and operates CommCare, a frontline worker data collection platform used in global health programs; SureAdhere is its patient-facing sibling product, enabling cross-sell into the same global public health footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCt8JcRhWywkVJRR_YWv4OhA
• LinkedInlinkedin.com/company/dimagi

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SureAdhere Mobile Technology